Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bumble Inc (BMBL) vs Enveric Biosciences Inc (ENVB) Price & Performance

Bumble IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Bumble Inc vs Enveric Biosciences Inc — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while Enveric Biosciences Inc trades at $1.56 (market cap $6.20M). The key difference: Bumble Inc is far larger — about 59.2× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.

BMBLENVB
Market Cap
$366.87M$6.20M
Sector
TechnologyHealth
52-Week High
$7.17$17.40
52-Week Low
$2.70$1.27
Enterprise Value
$672.73M$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bumble Inc

Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.

The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB